Point-of-Care Molecular Diagnostics Market Enrooted to US$11.1 Billion by 2033 with a CAGR of 9.7%

The Point-Of-Care Molecular Diagnostics Market is predicted to secure a valuation of US$ 4.4 billion in 2023 and is rising to US$ 11.1 billion by 2033. The market is estimated at a CAGR of 9.7% during the forecast period.

Rising infectious and chronic diseases, such as cardiovascular, diabetes, and COVID-19, are increasing the adoption of point-of-care molecular diagnostics. The demand for point-of-care molecular diagnostics is further increasing due to delayed testing results and high costs. Moreover, point-of-care molecular diagnostics manufacturers are growing the market opportunities by increasing production in the global market.

Access a World of Information with our Sample PDF Downloads. @ 
https://www.futuremarketinsights.com/reports/sample/rep-gb-14279

The growing advanced technology, diagnostic tests, preventive medicine, and knowledge of molecular mechanisms are driving the market growth. Furthermore, the adoption of point-of-care molecular diagnostics by laboratory specialist for sequencing DNA & multi-gene are expanding the market size. These diagnostics rapidly show the results with accuracy and are estimated to increase the sales of point-of-care molecular diagnostics.

Increasing respiratory, gastrointestinal, and sexually transmitted diseases are advancing the market growth. Emerging economies, government initiatives, and low-cost POC molecular diagnostics are the prime factors that propel market opportunities.

Factors Restraining the Market Growth

The market is going through a growth decline due to a few factors which are given below:

The dearth of consciousness about healthcare products, and poor penetration of advanced healthcare devices restrain market growth. The unavailability of advanced devices and the absence of government policies must gain market growth in developing countries.

Which Technology Category Booms the Market Growth?

The RT-PCR category dominates the global market with its remarkable CAGR of 9.2% during the foreseen time. The adoption of RT-PCR is rising due to the rise in tests such as genomics, COVID-19, proteomics, and others. It is a real-time system that shows results immediately, has high sensitivity, and costs efficiently. Due to the significant growth of infectious patients, healthcare providers are accelerating the demand for RT-PCR to provide patients with relevant data immediately.

Connect with Industry Experts and Get Expert Advice. Talk to Analyst@ 
https://www.futuremarketinsights.com/ask-question/rep-gb-14279

Key Takeaways:

-The point-of-care molecular diagnostics market is expected to have a valuation of US$ 11.1 billion by 2033.
-With a CAGR of 9.7%, the global market increasing from 2022 to 2033.
-The United States market is anticipated to capture a CAGR of 9.5% through 2033.
-With a CAGR of 8.8%, the United Kingdom market significantly uplifts during the forecast period.
-China market is expected to expand at a CAGR of 9.1% over the forecast period.
-Japan market is likely to capture a CAGR of 8.2% from 2023 to 2033.

Who is winning?

Key players fragment the global market by contributing an impressive role. These players are bringing new ideas and adapting them to build advanced products, which in turn surging market opportunities. Growing technologies, including Artificial Intelligence and the Internet of Things, have surpassed market growth in recent years.

By accepting these technologies, key players welcome better detection machines and equipment as per patients' requirements. They further follow several effective marketing strategies such as partnerships, mergers, acquisitions, agreements, and product launches.

Recent Developments:

-In Feb 2022, Sense Biodetection signed an agreement with Una Health to distribute COVID-19 testing equipment.
-In Dec 2021, FIND Company invested a valuation of US$ 21 million in S.D. Biosensor, Biomeme, Quaife, and Bioneer for manufacturing, developing and launching an affordable COVID-19 testing detector.
-A healthcare provider BioMérieux agreed to partner with Africa Medical Supplies Platform in Oct 2020 to supply premium quality COVID-19 diagnostic solutions.
-Abbott Laboratories announced its new COVID-19 detection product which can deliver results within minutes, in March 2020.
-In Oct 2018, QIAGEN agreed to enhance its portfolio with STAT-Dx to provide its customers with a next-generation PCR system.

Delve Deeper into the Subject by Clicking the Link Below Buy Complete Report@ 
https://www.futuremarketinsights.com/checkout/14279

Point-of-care Molecular Diagnostics Market Segmentation by Category

By Products & Services:

-Assays & Kits
-Instruments &Analyzers
-Software & Services

By Technology:

-RT-PCR
-INAAT
-Other Technologies

By Application:

-Respiratory Diseases
-Sexually Transmitted Diseases
-Hospital-acquired Infections
-Cancer
-Hepatitis
-Gastrointestinal Disorders
-Other Applications

By End User:

-Physicians' Offices
-Hospitals & ICUs
-Research Institutes
-Other End Users

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization, and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel, and End Use over the next 10 years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Click Here to Read The Full Report: @ https://www.futuremarketinsights.com/reports/point-of-care-molecular-diagnostics-market

This release was published on openPR.